Dynasty Wealth Management LLC Has $1.12 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Dynasty Wealth Management LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,302 shares of the medical research company’s stock after selling 442 shares during the quarter. Dynasty Wealth Management LLC’s holdings in Amgen were worth $1,121,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Private Trust Co. NA increased its stake in shares of Amgen by 6.0% in the fourth quarter. Private Trust Co. NA now owns 9,955 shares of the medical research company’s stock valued at $2,595,000 after buying an additional 560 shares in the last quarter. Argyle Capital Management LLC grew its holdings in Amgen by 2.0% during the 4th quarter. Argyle Capital Management LLC now owns 19,386 shares of the medical research company’s stock worth $5,053,000 after acquiring an additional 385 shares during the last quarter. Shoker Investment Counsel Inc. increased its position in Amgen by 1.2% in the 4th quarter. Shoker Investment Counsel Inc. now owns 10,184 shares of the medical research company’s stock valued at $2,654,000 after acquiring an additional 116 shares in the last quarter. Fusion Capital LLC raised its stake in shares of Amgen by 3.4% in the fourth quarter. Fusion Capital LLC now owns 23,805 shares of the medical research company’s stock worth $6,204,000 after acquiring an additional 783 shares during the last quarter. Finally, Fort Sheridan Advisors LLC lifted its position in shares of Amgen by 15.6% during the fourth quarter. Fort Sheridan Advisors LLC now owns 6,778 shares of the medical research company’s stock worth $1,766,000 after purchasing an additional 916 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $308.06 on Friday. The company has a market capitalization of $165.49 billion, a P/E ratio of 40.80, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The company’s 50 day moving average price is $280.87 and its two-hundred day moving average price is $300.16.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.09%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 126.09%.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Citigroup restated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Redburn Partners lowered their price target on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Piper Sandler boosted their price target on shares of Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Finally, Leerink Partners reduced their price objective on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $314.09.

Insider Activity

In related news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock worth $20,644,335 in the last quarter. Corporate insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.